Please assess the completion status of the following clinical trial:

Trial Title: EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented chronic, symptomatic iliac artery atherosclerotic disease (Rutherford/Becker category 1, 2, 3 or 4)~* Lifestyle-limiting claudication or rest pain~* De novo or restenotic lesions in the common and/or external iliac artery~* Subjects with bilateral disease may have only one target lesion treated per side~* Two target lesions may be treated with a maximum of two stents (if two target lesions are treated, each lesion must be covered with a maximum of one stent)~* Length of diseased segment(s) \<=13 cm and treatment is planned with no more than 2 overlapped Epic™ stents~* Baseline diameter stenosis \>= 50% (operator visual assessment)~* Reference vessel diameter \>= 5 mm and \<=11 mm~* At least one sufficient ipsilateral infrapopliteal run-off vessel~* Origin of profunda femoris artery is patent~Exclusion Criteria:~* Target vessel with in-stent restenosis~* Acute critical limb ischemia~* Tissue loss (Rutherford/Becker category 5 or 6)~* Any major amputations to the target limb~* Any minor amputation of the target limb in the last 12 months. If a minor amputation occurred greater than 12 months, stump needs to be completely healed.~* Life expectancy less than 24 months due to other medical co-morbid condition(s) that could limit the subject's ability to participate in the trial, limit the subject's compliance with the follow-up requirements, or impact the scientific integrity of the trial~* Known hypersensitivity or contraindication to contrast dye that, in the opinion of the investigator, cannot be adequately pre-medicated.~* Intolerance to antiplatelet, anticoagulant, or thrombolytic medications~* Platelet count \< 150,000 mm3 or \> 600,000 mm3~* Serum creatinine \> 2.0 mg/dL~* Dialysis-dependent end stage renal disease~* Pregnancy~* Current participation in another drug or device trial that has not completed the primary endpoint or that may potentially confound the results of this trial~* Known allergy to Nitinol~* Presence of arterial lesions (with the exception of renal, carotid or short, focal SFA lesions) requiring intervention within 30 days of the index procedure - Superficial femoral artery occlusion in the limb supplied by target vessel~* Heavily calcified and/or excessively tortuous lesions in the target vessel as determined by angiography~* Target lesion is within or near an aneurysm~* Persistent, intraluminal thrombus of the proposed target lesion post-thrombolytic therapy~* Perforated vessel as evidenced by extravasation of contrast media~* Vascular graft, aneurysm or postsurgical stenosis of the target vessel~* Multiple lesions in the same target vessel unable to be treated with a maximum of two stents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ORION (Type: EXPERIMENTAL): All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with iliac artery stenting with the Epic™ Nitinol Stent System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete